Notwithstanding any provision of this part 14 to the contrary, the board has no authority to perform an affordability review of, or to establish an upper payment limit for, any prescription drug that is derived in whole or in part from cannabis.
Source: L. 2021: Entire part added, (SB 21-175), ch. 240, p. 1276, § 2, effective June 16.